Brendan’s extensive experience as a senior clinical investigator fosters credible peer-to-peer conversations with prospective Teckro customers.

Brendan is a medical graduate of University College Cork (UCC) and a doctoral graduate in Biochemistry of Oxford University. He brings more than 40 years of experience in academic clinical practice as a physician in endocrinology, diabetes and clinical pharmacology.

Brendan is also a non-executive director of a number of biopharma development and services companies. He chairs the board of the leading Irish research charity, Fighting Blindness, and is a member of the board of Breakthrough Cancer Research. He was a member of the Board of Directors of the Irish Medicines Board (now the Health Products Regulatory Authority), chairing its statutory Advisory Committee for Human Medicines. In the past, he was also a member of the European Medicines Agency Committee for Orphan Medicinal Products (COMP) and of the European Medicines Agency (EMA) Scientific Advisory Committee on diabetes and metabolism.

Brendan is an Honorary Clinical Professor at UCC and an Adjunct Professor at University College Dublin in the respective medical faculties. He was Director of the European Collaborative Centre for Clinical Trials in Rare Diseases at UCC. With more than 150 scientific papers published in his career, Brendan also authored the opinion-leading book Re-Engineering Clinical Trials. He has directed a number of very large outcomes trials in metabolic/cardiovascular disease and chairs the independent data and safety monitoring boards for a number of large clinical development programs.

Brendan co-founded Firecrest Clinical, and when it was acquired by ICON served as Chief Medical Officer and Executive Vice President.

Dr. Brendan Buckley